Tracking of thermal microbial shock proteins and genomic variation of Bacillus cereus due to some abiotic stresses / Rastreamento de proteínas de choque microbiano térmico e variação genômica de Bacillus cereus devido a alguns estresses abióticos

Bacillus cereus is considered the most potent bacterial strain in terms of the increment in induced proteins during thermal treatment at 52 °C for 90 min. Protein production in food-born microorganism (Bacillus cereus) recovered from contaminated food was investigated in response to heat shock treatment. Bacterial tolerance towards pH, salinity, and temperature at various levels was also investigated. Heat-shock proteins (HSPs) produced when exposed to 52 °C for up to 60 minutes led to significant differences (30%) above the untreated control (37 °C), and the maximum difference was recorded at 52°C at 90 minutes. ISSR detected a higher number of bands/primer than RAPD (13.7 vs. 12.7, respectively), and more polymorphic bands (10.7 vs. 8.4 bands/primer, respectively). The untreated bacterial strain did not grow at pH levels lower than 3, whereas the thermally treated strain grew significantly at pH two. A consistent increase in HSPs was observed, with a gradual increase in salinity of less than 16%. Surprisingly, the gradual increase in temperature did not induce tolerance against higher temperatures. However, a significant growth rate was noticed in response to heat-shocked treatments. The untreated Bacillus cereus demonstrated antibiotic resistance to gentamycin and clindamycin (1.54 and 1.65 cm, respectively), much lower than the corresponding inhibition areas with preheat-treated test pathogen which were recorded (2.37 and 2.49 cm, respectively).

Bacillus cereus é considerada a cepa bacteriana mais potente em termos de incremento de proteínas induzidas durante o tratamento térmico a 52 °C por 90 min. A produção de proteínas em microorganismos de origem alimentar (Bacillus cereus) recuperados de alimentos contaminados foi investigada em resposta ao tratamento de choque térmico. A tolerância bacteriana ao pH, salinidade e temperatura em vários níveis também foram investigadas. Proteínas de choque térmico (HSPs) produzidas quando expostas a 52 °C por até 60 minutos levaram a diferenças significativas (30%) acima do controle não tratado (37 °C), e a diferença máxima foi registrada a 52 °C em 90 minutos . O ISSR detectou um maior número de bandas/iniciador do que o RAPD (13,7 vs. 12,7, respectivamente) e mais bandas polimórficas (10,7 vs. 8,4 bandas/iniciador, respectivamente). A cepa bacteriana não tratada não cresceu em níveis de pH abaixo de 3, enquanto a cepa tratada termicamente cresceu significativamente em pH dois. Observou-se aumento consistente de HSPs, com aumento gradual da salinidade inferior a 16%. Surpreendentemente, o aumento gradual da temperatura não induziu tolerância a temperaturas mais altas. No entanto, uma taxa de crescimento significativa foi observada em resposta aos tratamentos de choque térmico. O Bacillus cereus não tratado demonstrou resistência antibiótica à gentamicina e clindamicina (1,54 e 1,65 cm, respectivamente), muito menor do que as áreas de inibição correspondentes com patógeno de teste pré-tratado que foram registradas (2,37 e 2,49 cm, respectivamente).

Green coffee bean extract attenuates gentamicin induced acute nephrotoxicity in rats / El extracto de grano de café verde atenúa la nefrotoxicidad aguda inducida por gentamicina en ratas

Gentamicin induced acute nephrotoxicity (GIAN) is considered as one of the important causes of acute renal failure. In recent years' great effort has been focused on the introduction of herbal medicine as a novel therapeutic agent for prevention of GIAN. Hence, the current study was designed to investigate the effect of green coffee bean extract (GCBE) on GIAN in rats. Results of the present study showed that rat groups that received oral GCBE for 7 days after induction of GIAN(by a daily intraperitoneal injection of gentamicin for 7days), reported a significant improvement in renal functions tests when compared to the GIAN model groups. Moreover, there was significant amelioration in renal oxidative stress markers (renal malondialdehyde, renal superoxide dismutase) and renal histopathological changes in the GCBE-treated groups when compared to GIAN model group. These results indicate that GCBE has a potential role in ameliorating renal damage involved in GIAN.

La nefrotoxicidad aguda inducida por gentamicina (GIAN) se considera una de las causas importantes de insuficiencia renal aguda. En los últimos años, el gran esfuerzo se ha centrado en la introducción de la medicina herbal como un nuevo agente terapéutico para la prevención de GIAN. Por lo tanto, el estudio actual fue diseñado para investigar el efecto del extracto de grano de café verde (GCBE) sobre la GIAN en ratas. Los resultados del presente estudio mostraron que los grupos de ratas que recibieron GCBE oral durante 7 días después de la inducción de GIAN (mediante una inyección intraperitoneal diaria de gentamicina durante 7 días), informaron una mejora significativa en las pruebas de función renal en comparación con los grupos del modelo GIAN. Además, hubo una mejora significativa en los marcadores de estrés oxidativo renal (malondialdehído renal, superóxido dismutasa renal) y cambios histopatológicos renales en los grupos tratados con GCBE en comparación con el grupo del modelo GIAN. Estos resultados indican que GCBE tiene un papel potencial en la mejora del daño renal involucrado en GIAN.

Laboratory changes inherent to acute kidney injury induced by aminoglycosides in wistar rats / Alterações laboratoriais inerentes à lesão renal aguda induzida por aminoglicosídeos em ratos wistar

Acute kidney injury (AKI) is defined as an increase greater than 0.3 mg/L of serum creatinine within 48 hours and is a major cause of death in patients in intensive care units. Twenty-four Wistar rats were divided into three groups: Control (0.9% saline), Genta (gentamicin 50 mg.kg-¹ BID) and Deh+Genta (gentamicin 50 mg.kg-¹ BID + water restriction) and tested in an AKI model by aminoglycoside administration and dehydration implementation. The animals in the Deh+Genta group exhibited the lowest average weight and feed intake after the fifth day of the experiment. In this same period, water consumption by the Genta group was lower than the Control group, but in the following days of the experiment, polydipsia was noted for this group. The Deh+Genta group displayed the highest mean serum urea after the fifth day. The gentamicin-treated groups exhibited higher means than the Control group for serum creatinine, which proved to be a late renal marker for AKI. Serum GGT was higher in the Deh+Genta group, whereas urinary GGT was higher in the groups that received gentamicin, characterizing enzymuria, although severe dehydration can mask the results by indicating false negative values. The urinary GGT enzyme did not act as an early AKI biomarker. Decreased glomerular filtration rates enhanced the concentration of blood components and masked urinary and tissue components.

A lesão renal aguda (LRA) é definida como um aumento superior a 0,3 mg / L da creatinina sérica em 48 horas e é a principal causa de morte em pacientes em unidades de terapia intensiva. Vinte e quatro ratos Wistar foram divididos em três grupos: Controle (solução salina 0,9%), Genta (gentamicina 50 mg.kg-¹ BID) e Deh + Genta (gentamicina 50 mg.kg-¹ BID + restrição hídrica) e testados em um Modelo AKI por administração de aminoglicosídeos e sujeição à desidratação. Os animais do grupo Deh + Genta apresentaram o menor peso médio e o menor consumo de ração após o quinto dia de experimento. Nesse mesmo período, o consumo de água do grupo Genta foi inferior ao do grupo Controle, mas nos dias posteriores do experimento, o grupo Genta apresentou polidipsia. O grupo Deh + Genta apresentou média de uréia sérica mais elevada após o quinto dia. Os grupos tratados com gentamicina apresentaram médias superiores à do grupo Controle para a creatinina sérica, que se mostrou um marcador renal tardio de IRA. O valor de GGT sérico foi maior no grupo Deh + Genta, enquanto o valor de GGT urinário foi maior nos grupos que receberam gentamicina, caracterizando enzimúria, mas a desidratação severa pode mascarar os resultados por apresentar valores falsos negativos. A enzima GGT urinária não atuou como um biomarcador precoce de IRA. A diminuição da taxa de filtração glomerular aumentou a concentração de componentes do sangue e mascarou componentes urinários e teciduais.

Evaluación de la susceptibilidad de Enterococcus faecalis ATCC-29212 frente a medica- mentos combinados con hidróxido de calcio / Evaluation of the susceptibility of Enterococcus faecalis ATCC-29212 to drugs combined with calcium hydroxide

La elevada incidencia del Enterococcus faecalis en procedimientos odontológicos es un tópico de interés para el área de la salud, esta bacteria resiste a varios antimicrobianos y su proliferación aumenta debido a su baja susceptibilidad a sustancias de uso convencional como el hidróxido de calcio, convirtiéndose en una de las principales causas del fracaso de los tratamientos de conduc- to. La presente investigación evaluó la susceptibilidad in vitro del Enterococcus faecalis cepa ATCC-29212 frente a la combinación de sustancias y antibióticos con el hidróxido de calcio. Se utilizó la técnica de difusión en agar, inoculando el microorganismo en cajas de Petri con agar Cerebro Corazón (BHI), tratado con discos de papel filtro impregnados con 1µl de cada trata- miento por triplicado; T1 (Hidróxido de Calcio + propilenglicol), T2 (Hidróxido de Calcio + paramonoclorofenol), T3 (Hidróxido de Calcio + ampicilina gentamicina + propilenglicol), T4 (Hidróxido de Calcio + Solución Salina Fisiológica), Control positivo (medicamento comercial a base de Hidróxido de Calcio), se incubó a 35°C durante 24h, los halos formados alrededor de cada disco fueron medidos y comparados con la escala de Duraffourd y procesados mediante ANOVA de un factor. Se obtuvo una medida del halo de inhibición de 22,50±3,3 mm, con el trata- miento T3, siendo sumamente sensible. Concluyendo que este resultó el más efectivo en compa- ración el resto de la pruebas in vitro en comparación con el resto de los fármaco investigados.

The high incidence of Enterococcus faecalis in dental procedures is a topic of interest for the health area. This bacterium resists various antimicrobials and its proliferation increases due to its low susceptibility to substances of conventional use such as calcium hydroxide, becoming a of the main causes of root canal failure. The present investigation evaluated the in vitro suscepti- bility of Enterococcus faecalis strain ATCC-29212 to the combination of substances and antibio - tics with calcium hydroxide. The agar diffusion technique was used, inoculating the microorga- nism in Petri dishes with Brain Heart agar (BHI), treated with filter paper disks impregnated with 1µl of each treatment in triplicate; T1 (Calcium Hydroxide + propylene glycol), T2 (Cal- cium Hydroxide + paramonochlorophenol), T3 (Calcium Hydroxide + ampicillin gentamicin + propylene glycol), T4 (Calcium Hydroxide + Physiological Saline Solution), Positive control (Hydroxide-based commercial medicine Calcium), incubated at 35 ° C for 24h, the halos formed around each disc were measured and compared with the Duraffourd scale and processed by one-factor ANOVA. A measure of the inhibition halo of 22.50 ± 3.3 mm was obtained with the T3 treatment, being extremely sensitive. It was concluded that this was the most effective in comparison with the rest of the in vitro tests of the rest of the investigated drugs.

Terapia vestibular en vestibulopatía bilateral por gentamicina: reporte de un caso y revisión de la literatura / Vestibular therapy in a case of gentamicin-induced vestibulopathy: case report and literature revision

La vestibulopatía bilateral es poco frecuente, se caracteriza principalmente por inestabilidad al caminar o al estar de pie, visión borrosa inducida por el movimiento u oscilopsia al caminar o al realizar movimientos rápidos de la cabeza o del cuerpo, empeoramiento de la estabilidad en la oscuridad o terrenos irregulares, reducción de los síntomas al estar en condiciones estáticas, ganancia del reflejo vestíbulo-ocular angular reducida de forma bilateral, entre otros. Existen múltiples causas. Dentro de las causas identificables, se describen principalmente medicamentos ototóxicos, meningitis y enfermedad de Ménière. Se presenta el caso de una paciente de 64 años diagnosticada con vestibulopatía bilateral posterior a tratamiento intramuscular con gentamicina por sobreinfección bacteriana cutánea de las manos. La evaluación vestibular complementada con videonistagmografía y prueba de impulso cefálico asistida por video confirman el diagnóstico y se inicia tratamiento con rehabilitación vestibular enfocada en promover la compensación central a través de estrategias de sustitución principalmente; además de habituación y adaptación vestibular, favoreciendo la estabilización de la mirada, mantención del equilibrio, control postural, marcha y reducción de los síntomas.

Bilateral vestibulopathy is infrequent, and it is characterized mostly by unstable walking or when standing, blurred vision induced by movement, or oscillopsia when walking or performing fast movements; worsening of the stability in darkness or uneven ground, but with lack of symptoms in static conditions. Other symptoms may include bilateral reduction of the oculo-vestibular reflex. Among the identifiable causes, there is the use of ototoxic medication, meningitis, Ménière's disease, although it can be idiopathic or have a neurological cause. We hereby describe the case of a 64-year-old woman, diagnosed with bilateral vestibulopathy secondary to intramuscular treatment with gentamicin due to a bacterial hand infection. Vestibular assessment was complemented with video-nystagmography and video head impulse test which confirmed the diagnosis, and therapy was started with vestibular rehabilitation focused on promoting central compensation mainly, through substitution strategies. Also, habituation exercise and vestibular adaptation strategies were used, thus promoting sight stabilization, balance maintenance, postural control, walking, and reduction of the symptoms.

Companion psittacine birds as reservoir of gentamicin and vancomycin-resistant Enterococcus spp / Psitacídeos de companhia como reservatórios de Enterococcus spp. gentamicina e vancomicina-resistentes

Enterococcus are recognized worldwide as significant nosocomial agents that have been continuously envolving to adapt to different niches and acquire resistance to several antibiotic classes. Vancomycin and gentamicin-resistant strains of E. faecalis and E. faecium have been associated with nosocomial human infections. Some epidemiological studies suggest the participation of pets as reservoirs of vancomycin and gentamicin-resistant Enterococcus strains. However, the role of companion birds as reservoirs of these strains has been poorly studied. In this study, 126 psittacine birds were evaluated and 26.9% carried Enterococcus spp., including the species E. faecalis, E. faecium, E. hirae, E. phoeniculicola, E. gallinarum and E. casseliflavus. The antibiotic resistance profile showed four high-level gentamicin-resistance (HLGR) strains. In addition, two strains presented intermediate levels of vancomycin resistance. Resistant strains were isolated from fecal and oropharynx samples of sick and clinically healthy birds, suggesting that psittacine birds may act as reservoirs of HLGR Enterococcus spp. However, sick birds appear to be more implicated in the enterococci transmission than healthy birds.(AU)

Enterococcus são reconhecidos mundialmente como significantes agentes nosocomiais, que têm continuamente se adaptado a diferentes nichos e adquirido resistência a várias classes de antibióticos. Cepas de E. faecalis e E. faecium vancomicina e gantamicina-resistentes têm sido associadas a infecções nosocomiais em humanos. Alguns estudos epidemiológicos sugerem a participação de aves como reservatórios de cepas de Enterococcus vancomicina e gentamicina-resistentes. Entretanto, a relação das aves de companhia como reservatórios destas cepas tem sido pouco estudada. Neste estudo, 126 psitacídeos foram avaliados, e 26,9% destes eram portadores de Enterococcus spp., incluindo as espécies E. faecalis, E. faecium, E. hirae, E. phoeniculicola, E. gallinarum e E. casseliflavus. O perfil de resistência antibiótica mostrou quatro cepas com alto nível de resistência a gentamicina (ANRG). Além de duas cepas com nível intermediário de resistência a vancomicina. As cepas resistentes foram isoladas de amostras fecais e de orofaringe de aves doentes e clinicamente saudáveis, sugerindo que psitacídeos podem estar atuando como reservatórios para Enterococcus spp. com ANRG. Contudo, Aves doentes parecem estar mais relacionadas à transmissão de enterococcus, do que aves saudáveis.(AU)

Companion psittacine birds as reservoir of gentamicin and vancomycin-resistant Enterococcus spp / Psitacídeos de companhia como reservatórios de Enterococcus spp. gentamicina e vancomicina-resistentes

Enterococcus are recognized worldwide as significant nosocomial agents that have been continuously envolving to adapt to different niches and acquire resistance to several antibiotic classes. Vancomycin and gentamicin-resistant strains of E. faecalis and E. faecium have been associated with nosocomial human infections. Some epidemiological studies suggest the participation of pets as reservoirs of vancomycin and gentamicin-resistant Enterococcus strains. However, the role of companion birds as reservoirs of these strains has been poorly studied. In this study, 126 psittacine birds were evaluated and 26.9% carried Enterococcus spp., including the species E. faecalis, E. faecium, E. hirae, E. phoeniculicola, E. gallinarum and E. casseliflavus. The antibiotic resistance profile showed four high-level gentamicin-resistance (HLGR) strains. In addition, two strains presented intermediate levels of vancomycin resistance. Resistant strains were isolated from fecal and oropharynx samples of sick and clinically healthy birds, suggesting that psittacine birds may act as reservoirs of HLGR Enterococcus spp. However, sick birds appear to be more implicated in the enterococci transmission than healthy birds.(AU)

Enterococcus são reconhecidos mundialmente como significantes agentes nosocomiais, que têm continuamente se adaptado a diferentes nichos e adquirido resistência a várias classes de antibióticos. Cepas de E. faecalis e E. faecium vancomicina e gantamicina-resistentes têm sido associadas a infecções nosocomiais em humanos. Alguns estudos epidemiológicos sugerem a participação de aves como reservatórios de cepas de Enterococcus vancomicina e gentamicina-resistentes. Entretanto, a relação das aves de companhia como reservatórios destas cepas tem sido pouco estudada. Neste estudo, 126 psitacídeos foram avaliados, e 26,9% destes eram portadores de Enterococcus spp., incluindo as espécies E. faecalis, E. faecium, E. hirae, E. phoeniculicola, E. gallinarum e E. casseliflavus. O perfil de resistência antibiótica mostrou quatro cepas com alto nível de resistência a gentamicina (ANRG). Além de duas cepas com nível intermediário de resistência a vancomicina. As cepas resistentes foram isoladas de amostras fecais e de orofaringe de aves doentes e clinicamente saudáveis, sugerindo que psitacídeos podem estar atuando como reservatórios para Enterococcus spp. com ANRG. Contudo, Aves doentes parecem estar mais relacionadas à transmissão de enterococcus, do que aves saudáveis.(AU)

Utilización de Gentamicina y Amoxicilina tableta en el Centro de Atenciones de Emergencias (CAE-SAN MARTIN) del FOSALUD, San Salvador, El Salvador. 2018¯ / Use of Gentamicin and Amoxicillin Tablet at fosALUD Emergency Care Center (CAE-SAN MARTIN), San Salvador, El Salvador. 2018

Objetivos: Determinar la utilización de Gentamicina y Amoxicilina tableta en el Centro de Atenciones de Emergencias (CAE-SAN MARTIN) del FOSALUD durante el año 2018. Diseño: Estudio de Descriptivo Retrospectivo, el estudio se realizó el Centro de Atención de Emergencias CAE- San Martin perteneciente a la institución Fondo Solidario para la Salud (FOSALUD). Se comparó el diagnostico con la cantidad prescrita para determinar si había cumplimiento de normativa. Resultados: Para el caso de usuarios de Amoxicilina la mayor procedencia corresponde al municipio de San Martin con un 75%, seguido de San Pedro Perulapán con un 16.25 %. La distribución por sexo está distribuida de forma homogénea entre ambos sexos. La gentamicina se utilizó en mayor porcentaje en mujeres. La principal causa de consulta para amoxicilina tableta fue faringitis aguda, no especificada, y para el caso de gentamicina fue infección de vías urinarias, sitio no especificado. Conclusiones: Para el caso de la Amoxicilina se concluye que entre las primeras diez causas de consulta no se observa que se exceda de la cantidad máxima (30) a prescribir, por lo que cumple con los lineamientos en cuanto a cantidades a prescribir. Para el caso de la Gentamicina se concluye que en la totalidad de los diagnósticos en los cuales se prescribió no se observa que se exceda de la cantidad máxima a prescribir (14)

Uso de gentamicina transtimpánica: experiencia del Hospital Clínico de la Universidad de Chile / Transtympanic gentamicin: experience in Hospital Clínico Universidad de Chile

RESUMEN Introducción: La gentamicina transtimpánica se utiliza en el manejo de pacientes con vértigo crónico refractario al manejo médico. Objetivo: Describir y analizar las características clínicas, epidemiológicas, y resultados de pacientes sometidos a tratamiento con gentamicina transtimpánica en el Hospital Clínico de la Universidad de Chile. Material y método: Estudio retrospectivo, descriptivo, incluyendo los pacientes con patología otorrinolaringológica que hayan recibido gentamicina transtimpánica entre los años 2008 y 2018. Se analizaron variables epidemiológicas, clínicas, y función vestibular. Resultados: La serie está constituida por diez pacientes, con una edad promedio de 52,4 años; siete mujeres y tres hombres. El diagnóstico fue en su mayoría enfermedad de Ménière (7 pacientes). El número promedio de inyecciones de gentamicina fue de 2,8. En el período de seguimiento (rango 1-96 meses), se logró mejoría del vértigo en la mayoría de los pacientes (8 de 10). Conclusión: El tratamiento con inyecciones de gentamicina transtimpánica es una opción importante para aliviar la sintomatología de pacientes con vértigo crónico intratable. Debe indicarse en casos seleccionados, y siempre realizar un estudio auditivo y vestibular completo antes y después del tratamiento con gentamicina.

ABSTRACT Introduction: Transtympanic gentamicin is used for treatment of patients with chronic vertigo refractory to medical management. Aim: To describe and analyze the clinical outcome of patients whom underwent treatment with transtympanic gentamicin at the Clinical Hospital Universidad de Chile. Material and method: Retrospective and descriptive study including patients with otolaryngologist disease whom underwent treatment with transtympanic gentamicin between 2008 and 2018. Epidemiological, clinical variables and vestibular function were analyzed. Results: The serie consists of ten patients, 7 men and 3 women, with an average age of 52,4 years. The most frequent diagnosis was Ménière disease (7 patients). The average number of gentamicin injections was 2,8. The follow up varies from 1 to 96 months, presenting improvement of vertigo in the majority of the cases (8 of 10 patients). Conclusion: The treatment with transtympanic injections of gentamicin is a relevant option to decrease symptoms in patients with chronic intractable vertigo. It should be indicated in selected patients. Prior and posterior the treatment, patients must be studied with a complete evaluation of the auditory and vestibular function.

Efecto nefroprotector del Camu Camu (Myrciaria dubia) en un modelo de nefrotoxicidad inducida por gentamicina en ratas / Nephroprotective effect of Camu Camu (Myrciaria dubia) in a model of nephrotoxicity induced by Gentamicin in rats

RESUMEN El objetivo del estudio fue determinar el efecto nefroprotector del extracto de camu camu en un modelo de nefrotoxicidad inducida por la gentamicina. Estudio de tipo experimental formado por 50 ratas Sprague Dawley que se dividieron aleatoriamente en cinco grupos de estudio: Al grupo control se le administró la solución salina, al grupo gentamicina se le indujo la nefrotoxicidad y a los grupos experimentales 1, 2 y 3 se les protegió con el extracto alcohólico de camu camu a diferentes dosis. La actividad nefroprotectora se evaluó por la cuantificación de la creatinina sérica, el peso y análisis histopatológico de los riñones. Los resultados evidenciaron una disminución significativa del nivel de creatinina en los grupos protegidos con el extracto alcohólico de camu camu con respecto al grupo gentamicina (p<0,05). Los grupos que recibieron camu camu presentaron un aumento gradual del peso de los riñones en una relación directa a la dosis del extracto (p<0,05). El análisis histológico evidenció pérdida epitelial, infiltrado inflamatorio intenso y congestión vascular en el grupo gentamicina, mientras que los grupos que recibieron camu camu con el extracto disminuyeron la gravedad del daño. Se concluye que el extracto de camu camu presentó una actividad nefroprotectora significativa en un modelo de nefrotoxicidad inducida por gentamicina.

ABSTRACT The aim of the study was to determine the nephroprotective effect of camu camu extract on a gentamicin-induced nephrotoxicity model. The study design was experimental using 50 Sprague Dawley rats randomly allocated into 1 of 5 five groups: a control group that was administered a saline solution, a gentamicin group in which nephrotoxicity was induced and experimental groups 1, 2 and 3 that were provided different doses of Camu Camu alcoholic extract. Nephroprotective activity was evaluated via quantification of seric creatinine, histopathological analysis and weighing of the kidneys. Results showed a significant decrease in creatinine levels between the group administered camu camu alcoholic extract and the gentamicin group (p<0.05). Groups who received camu camu presented a gradual increase in kidneys weight which corresponded directly to the extract dose (p<0.05). The histopathological analysis showed epithelial loss, intense inflammatory infiltrate and vascular congestion in the gentamicin group, while the groups who received the extract had a lower level of damage. Camu Camu extract provided a significant nephroprotective activity on a gentamicin-induced nephrotoxicity model.

Evaluación de la eficacia de fosfomicina trometamol y gentamicina en la profilaxis de la cistoscopia flexible tras el estudio de los patógenos de nuestro entorno / Evaluation of the Efficacy of Fosfomycin Trometamol and Gentamicin in the Prophylaxis of Flexible Cystoscopy after the Study of Microflora in our Environment

Objetivo Optimizar el uso de antibióticos en la profilaxis de la cistoscopia flexible estudiando los patógenos más frecuentes de nuestro entorno y eligiendo el antibiótico según sus antibiogramas. Métodos Desde Enero del 2015 hasta Noviembre del 2015, se analizaron los urinocultivos de nuestra área, se eligió el antibiótico en función a su sensibilidad frente a los patógenos más frecuentes y se comparó con un antibiótico de amplio espectro. Desde Enero del 2016 hasta Diciembre del 2016, se realizaron las cistoscopias agrupando a los pacientes en: Grupo 1: Pacientes sin profilaxis; Grupo 2: Profilaxis con Gentamicina 240 mg; Grupo 3: Profilaxis con antibiótico seleccionado. Como variables principales se definieron la presencia de bacteriuria asintomática e ITU tras la realización de la cistoscopia flexible. Resultados Se analizaron 8.530 urinocultivos y se eligió la Fosfomicina Trometamol 3 gr como profilaxis. Se realizaron 244 cistoscopias distribuidas: Grupo 1: 86 (35%); Grupo 2: 72 (30%); Grupo 3: 86 (35%). Se detectó bacteriuria asintomática postcistoscopia en 6 pacientes (2,5%) en el Grupo 1, 7 pacientes (2,9%) en el grupo 2 y 5 pacientes (2%) en el grupo 3 no presentando diferencias significativas (p 0.120). Desarrollaron ITUs postcistoscopia 1 paciente (0,4%) en el Grupo 1, 5 pacientes (2%) en el Grupo 2 y 2 pacientes (0,8%) en el Grupo 3 sin diferencias significativas (p 0.105). Conclusión La Fosfomicina es tan efectiva como la Gentamicina en la profilaxis de la cistoscopia. Para un uso correcto de los antibióticos, se recomienda el estudio de los patógenos de nuestro entorno.

Objective To optimize the use of antibiotics in the prophylaxis of flexible cystoscopy by studying the most frequent pathogens in our environment and choosing the antibiotic according to its antibiograms. Method Between January 2015 and November 2015, urine cultures were analyzed in our area, the antibiotic was chosen based on its sensitivity to the most frequent pathogens and compared with a broad spectrum antibiotic. From January 2016 to December 2016, cystoscopy was performed by grouping patients into: Group 1 - Patients without prophylaxis, Group 2 - Prophylaxis with 240 mg gentamicin, Group 3 - Selected antibiotic prophylaxis. The main variables were the presence of asymptomatic bacteriuria and UTI after flexible cystoscopy. Results 8530 urine cultures were analyzed and 3 g of fosfomycin trometamol was chosen as the prophylactic. There were 244 cystoscopies: Group 1: 86 (35%); Group 2: 72 (30%); Group 3: 86 (35%). Asymptomatic bacteriuria was detected in 6 patients (2.5%) in Group 1, 7 patients (2.9%) in Group 2 and 5 patients (2%) in Group 3, showing no significant differences (p = 0.120). Post-cystoscopic urinary tract infection developed in 1 patient (0.4%) in Group 1, 5 patients (2%) in Group 2 and 2 patients (0.8%) in Group 3, which showed no significant differences (p 0.105). Conclusion Fosfomycin is as effective as Gentamicin as a prophylactic in cystoscopy. The study of the pathogens in each environment is recommended to correctly prescribe the antibiotic.

The effect of gentamicin nephrotoxicity in newborn mice at breastfeeding / El efecto de la nefrotoxicidad por gentamicina en ratones recién nacidos durante la lactancia

Gentamicin can pass through the placenta. This antibiotic also enters breast milk, but its absorption in the intestine is insignificant, so that it could be only found in half of the infants' blood. In the present study, it is attempted to experimentally evaluate the toxic effect of gentamicin on the kidneys of newborn mice in breastfeeding. This study was performed on 20 female Balb/c pregnant mice weighing 30 to 35 g. The female pregnant mice were randomly divided to two groups of 10. The lactating mothers were intraperitoneally injected with gentamicin at 200 mg/kg every other day sequentially, and the normal group was injected with normal saline at the same volume. Blod samples were collected from the heart of the newborns for the evaluation of renal function. The samples were passing paraffin blocks and were staining with hematoxylin and eosin. The data were expressed as mean±SE and T-test was used. In the observations of kidney tissues of the newborns treated with gentamicin, there were several tissue injuries in comparison with the normal group such as lytic necrosis with picnotic nucleus occurred in the epithelium cells of kidney tubules. Moreover, in some epithelium cells of tubules, degeneration changes of the kind of hydropic and cytoplasmic vacuolation were observed. In the current study, though gentamicin had no significant effect on anomalies in newborns. it indicated however, that the intervention breastfeeding could have pathological effects and consequently, cause changes in the function factors of the kidneys of newborns.

La gentamicina puede pasar a través de la placenta. Este antibiótico también ingresa en la leche materna, pero su absorción en el intestino es insignificante, por lo que solo se puede encontrar en la mitad de la sangre de los recién nacidos. En el presente estudio, se intentó evaluar experimentalmente el efecto tóxico de gentamicina en los riñones de ratones recién nacidos durante la lactancia. Este estudio se realizó en 20 hembras preñadas con un peso entre 30 y 35 g. Las hembras lactantes se dividieron aleatoriamente en dos grupos de 10 animales. Las madres que amamantaron fueron tratadas con gentamicina (200 mg/kg, vía intraperitoneal), cada dos días secuencialmente, y al grupo normal se le inyectó solución salina normal en el mismo volumen. Se tomaron muestras de sangre del corazón de los recién nacidos para la evaluación de la función renal. Las muestras pasaron por bloques de parafina y se tiñeron con hematoxilina y eosina. Los datos se expresaron como media ± DE y t-test. En comparación con el grupo normal, se observaron varias lesiones en los tejidos del riñón de los ratones recién nacidos tratados con gentamicina, tal como como necrosis lítica con núcleo picnótico en las células del epitelio de los túbulos renales. Además, en algunas células del epitelio de los túbulos renales, se observaron cambios degenerativos del tipo de vacuolación hidrópica y citoplásmica. En el estudio actual, la gentamicina no tuvo un efecto significativo sobre las anomalías en los recién nacidos. Sin embargo, observamos que la intervención de amamantamiento podría tener efectos patológicos y, en consecuencia, causar cambios en los factores funcionales de los riñones en recién nacidos.

Diabetes Mellitus: fator de risco para toxicidade de medicamentos / Diabetes Mellitus: factor de riesgo para toxicidad de fármacos / Diabetes Mellitus: a risk factor for drug toxicity

RESUMO Objetivo Avaliar o efeito do antibiótico gentamicina em modelo experimental na presença de Diabetes Mellitus por meio da função renal e perfil oxidativo. Método Ratos Wistar, adultos, machos, foram distribuídos nos grupos: Citrato; Gentamicina (Genta), (gentamicina 100 mg/kg de peso corporal, 1 vez ao dia, intraperitoneal, i.p., 5 dias); DM (60 mg/kg de STZ, intravenosa, i.v., dose única, diluída em tampão citrato) e DM+Genta. Foram avaliados os parâmetros fisiológicos, a função renal (clearance de creatinina), a lesão oxidativa (peróxidos e substâncias reativas ao ácido tiobarbitúrico − TBARS urinários) e a hemodinâmica renal. Resultados O grupo Diabetes Mellitus apresentou hiperglicemia crônica, associada à perda de peso corporal, polifagia, polidipsia e poliúria, além de redução da função renal, com aumento na excreção de metabólitos oxidativos. A administração de gentamicina induziu a redução do fluxo sanguíneo renal e o aumento da resistência vascular renal em ratos saudáveis. A associação do Diabetes Mellitus com gentamicina resultou em redução adicional na função renal e elevação de metabólitos oxidativos, com aumento de resistência vascular renal. Conclusão A existência de Diabetes Mellitus determinou a elevação da nefrotoxicidade da gentamicina e se confirmou como fator de risco para nefrotoxicidade de medicamentos.

RESUMEN Objetivo Evaluar el efecto del antibiótico gentamicina en modelo experimental en la presencia de Diabetes Mellitus mediante la función renal y el perfil oxidativo. Método Ratas Wistar, adultas, machos, fueron distribuidas en los grupos: Citrato; Gentamicina (Genta), (gentamicina 100 mg/kg de peso corporal, 1 vez al día, intraperitoneal, i.p., 5 días); DM (60 mg/kg de STZ, intravenosa, i.v., dosis única, diluida en tampón citrato) y DM+Genta. Fueron evaluados los parámetros fisiológicos, la función renal (aclaramiento de creatinina), la lesión oxidativa (peróxidos y sustancias reactivas al ácido tiobarbitúrico - TBARS urinarios) y la hemodinámica renal. Resultados El grupo Diabetes Mellitus presentó hiperglucemia crónica, asociada con pérdida de peso corporal, polifagia, polidipsia y poliuria, además de reducción de la función renal, con aumento en la secreción de metabolitos oxidativos. La administración de gentamicina indujo a la reducción del flujo sanguíneo renal y al incremento de la resistencia vascular renal en ratas sanas. La asociación del Diabetes Mellitus con gentamicina resultó en reducción adicional en la función renal y elevación de metabolitos oxidativos, con aumento de resistencia vascular renal. Conclusión La existencia de Diabetes Mellitus determinó la elevación de la nefrotoxicidad de la gentamicina y se confirmó como factor de riesgo para nefrotoxicidad de fármacos.

ABSTRACT Objective To assess the effect of the antibiotic Gentamicin in an experimental model in the presence of Diabetes Mellitus through renal function and oxidative profile. Method Adult male Wistar rats were distributed into groups: Citrate; Gentamicin (Genta), (intraperitoneal, i.p. gentamicin, 100 mg/kg of body weight, once a day,5 days); DM (60 mg/kg of STZ (Streptozotocin), single dose, intravenously, i.v., diluted in citrate buffer); and DM+Genta. Physiological parameters, renal function (creatinine clearance), oxidative damage (peroxides and thiobarbituric acid reactive substances - urinary TBARS) and renal hemodynamics were evaluated. Results The Diabetes Mellitus group presented chronic hyperglycemia associated with loss of body weight, polyphagia, polydipsia and polyuria, in addition to reduced renal function and with an increase in oxidative metabolite excretion. Administration of gentamicin induced a reduction in renal blood flow and increased renal vascular resistance in healthy rats. The association of Diabetes Mellitus with gentamicin resulted in an additional reduction in renal function and elevation of oxidative metabolites, with increased renal vascular resistance. Conclusion The existence of Diabetes Mellitus resulted in an elevation of gentamicin nephrotoxicity, thus confirming the risk factor for drug nephrotoxicity.

Laberintectomía quirúrgica / Surgical labyrinthectomy

El tratamiento quirúrgico del vértigo se puede dividir en dos grandes grupos: no ablativos y ablativos, dentro de éstos últimos se encuentra la laberintectomía quirúrgica, técnica con la cual se produce cofosis. Su principal indicación es la sintomatología vestibular periférica invalidante, unilateral, que no mejora con medidas farmacológicas ni con terapia psiquiátrica, asociado a hipoacusia sensorioneural severa a profunda. Existen dos tipos de abordajes para realizar la laberintectomía quirúrgica: transmastoidea y transcanal, siendo la primera el gold standard para eliminar la función vestibular. Se presentarán dos casos clínicos de pacientes sometidos a estos procedimientos, uno por vía transmastoidea y otro por vía transcanal.

The surgical treatment of vertigo can be classified into two main groups: non-ablative and ablative. The surgical labyrinthectomy is an ablative treatment in which no hearing is preserved. Its main indication is the disabling peripherical and unilateral vestibular symptoms that do not improve with pharmacological measures or with psychiatric therapy, in patients with severe to profound sensorineural hearing loss. There are two types of approaches for labyrinthectomy, transmastoid and transcanal, the first is the gold standard to eliminate the vestibular function. Here, we present two cases of patients undergoing these procedures, one by transmastoid approach and the other by transcanal approach.

Refractory episodic vertigo: role of intratympanic gentamicin and vestibular evoked myogenic potentials / Vertigem refratária episódica: papel da gentamicina intratimpânica e potencial evocado miogênico vestibular

Abstract Introduction: Even today, the treatment of intractable vertigo remains a challenge. Vestibular ablation with intratympanic gentamicin stands as a good alternative in the management of refractory vertigo patients. Objective: To control intractable vertigo through complete saccular and horizontal canal vestibular ablation with intratympanic gentamicin treatment. Methods: Patients with refractory episodic vertigo were included. The inclusion criteria were: unilateral ear disease, moderate to profound sensorineural hearing loss, and failure to other treatments. Included patients underwent 0.5-0.8 mL of gentamicin intratympanic application at a 30 mg/mL concentration. Vestibular ablation was confirmed by the absence of response on cervical vestibular evoked myogenic potentials and no response on caloric tests. Audiometry, electronystagmography with iced water, and vestibular evoked myogenic potentials were performed in all patients. Results: Ten patients were included; nine patients with Meniere's disease and one patient with (late onset) delayed hydrops. Nine patients showed an absent response on vestibular evoked myogenic potentials and no response on caloric tests. The only patient with low amplitude on cervical vestibular evoked myogenic potentials had vertigo recurrence. Vertigo control was achieved in 90% of the patients. One patient developed hearing loss >30 dB. Conclusions: Cervical vestibular evoked myogenic potentials confirmed vestibular ablation in patients treated with intratympanic gentamicin. High-grade vertigo control was due to complete saccular and horizontal canal ablation (no response to iced water in electronystagmography and no response on cervical vestibular evoked myogenic potentials).

Resumo Introdução: Ainda hoje, o controle da vertigem intratável permanece um desafio. A ablação vestibular com gentamicina intratimpânica permanece como uma boa alternativa no tratamento de pacientes com vertigem refratária. Objetivo: Controlar a vertigem intratável por meio de ablação vestibular completa dos canais sacular e horizontal com gentamicina intratimpânica como tratamento. Método: Pacientes com vertigem refratária episódica foram incluídos. Os critérios de inclusão foram doença unilateral da orelha, perda auditiva neurossensorial de moderada a profunda e fracasso com outros tratamentos. Os pacientes incluídos receberam uma aplicação de 0,5-0,8 mL de gentamicina intratimpânica com concentração de 30 mg/mL. A ablação vestibular foi confirmada pela ausência de resposta no teste de potencial evocado miogênico vestibular cervical (PEMVc) e nenhuma resposta nas provas calóricas. Audiometria, eletronistagmografia com água gelada e potencial evocado miogênico vestibular foram realizados em todos os pacientes. Resultados: Ao todo, dez pacientes foram incluídos: nove com doença de Ménière e um com hidropisia tardia. Nove pacientes apresentaram ausência de resposta no teste de potencial evocado miogênico vestibular e nenhuma resposta na prova calórica. O único paciente com baixa amplitude no PEMVc apresentou recorrência da vertigem. O controle da vertigem foi obtido em 90% dos pacientes. Um paciente desenvolveu perda auditiva > 30 dB. Conclusões: O PEMVc confirmou ablação vestibular nos pacientes tratados com gentamicina intratimpânica. O alto grau de controle da vertigem foi devido à ablação completa do sáculo e canal horizontal (sem resposta à água gelada na eletronistagmografia e ausência de resposta no PEMVc).

Resistencia a oxacilina, eritromicina y gentamicina en cepas de Staphylococcus coagulasa negativa aisladas de hemocultivos / Resistance to oxacillin, erythromycin and gentamycin in coagulase negative Staphylococcus strains isolated from blood cultures

La resistencia a los antimicrobianos en bacterias Gram positivas como Staphylococcus coagulasa negativa constituye una amenaza mundial emergente. El propósito de la presente investigación fue identificar los genes de resistencia a oxacilina (mecA), eritromicina (erm y msrA), y gentamicina aac(6´)/aph(2´´), en cepas de Staphylococcus coagulasa negativa aisladas de hemocultivos de pacientes atendidos en el Hospital Universitario de Maracaibo. La detección fenotípica se realizó mediante métodos automatizados. Se utilizó la reacción en cadena de la polimerasa para detectar la presencia de genes de resistencia a los antimicrobianos. Se estudiaron 34 cepas cuya distribución por especie fue: S. haemolyticus (38,23%), S. epidermidis (29,42%), S. hominis (26,47%), S. xylosus y S. capitis (5,88% cada uno). Todas las cepas fueron resistentes a oxacilina. La resistencia a gentamicina varió entre 38,46% y 100%; mientras que la resistencia a eritromicina osciló entre 77,78% y 100%. Los análisis mostraron la presencia de los genes mecA (100%), ermA (35,2%), ermC (41,17%), msrA (17,64%), y aac(6´)/aph(2´´) (61,76%). En conclusión, se encontró una alta frecuencia de genes de resistencia a estos antibióticos y la Unidad de Cuidados Intensivos fue el servicio médico donde se aisló el mayor porcentaje de cepas portadoras de estos genes.

Resistance to antimicrobials in Gram-positive bacteria such as coagulase negative Staphylococcus is an emerging global threat. The purpose of this research was to identify the genes for resistance to oxacillin (mecA), erythromycin (erm and msrA), and gentamicin aac(6´)/aph(2´´), in Staphylococcus coagulase negative strains isolated from blood cultures from patients attended at the University Hospital in Maracaibo. Phenotypic detection was performed using automated methods. Polymerase chain reaction was used for the detection of antimicrobial resistance genes. Be studied 34 strains whose distribution by species was: S. haemolyticus (38.23%), S. epidermidis (29.42%), S. hominis (26.47%), S. xylosus and S. capitis (5.88% each one). All strains were resistant to oxacillin. Gentamicin resistance varied between 38.46% and 100%; while the erythromycin resistance ranged between 77.78% and 100%. The analyses showed the presence of genes mecA (100%), ermA (35.2%), ermC (41.17%), msrA (17.64%), and aac(6´)/aph (2´´) (61,76%). In conclusion, is found a high frequency of genes for resistance to these antibiotics and the intensive care unit was the health service where the highest percentage of isolated strains carriers of these genes.

Refractory episodic vertigo: role of intratympanic gentamicin and vestibular evoked myogenic potentials.

INTRODUCTION: Even today, the treatment of intractable vertigo remains a challenge. Vestibular ablation with intratympanic gentamicin stands as a good alternative in the management of refractory vertigo patients. OBJECTIVE: To control intractable vertigo through complete saccular and horizontal canal vestibular ablation with intratympanic gentamicin treatment. METHODS: Patients with refractory episodic vertigo were included. The inclusion criteria were: unilateral ear disease, moderate to profound sensorineural hearing loss, and failure to other treatments. Included patients underwent 0.5-0.8mL of gentamicin intratympanic application at a 30mg/mL concentration. Vestibular ablation was confirmed by the absence of response on cervical vestibular evoked myogenic potentials and no response on caloric tests. Audiometry, electronystagmography with iced water, and vestibular evoked myogenic potentials were performed in all patients. RESULTS: Ten patients were included; nine patients with Meniere's disease and one patient with (late onset) delayed hydrops. Nine patients showed an absent response on vestibular evoked myogenic potentials and no response on caloric tests. The only patient with low amplitude on cervical vestibular evoked myogenic potentials had vertigo recurrence. Vertigo control was achieved in 90% of the patients. One patient developed hearing loss >30dB. CONCLUSIONS: Cervical vestibular evoked myogenic potentials confirmed vestibular ablation in patients treated with intratympanic gentamicin. High-grade vertigo control was due to complete saccular and horizontal canal ablation (no response to iced water in electronystagmography and no response on cervical vestibular evoked myogenic potentials).

Parámetros farmacocinéticos de gentamicina en recién nacidos de término: ¿Es necesario monitorizar en forma sistemática sus concentraciones plasmáticas? / Gentamicin pharmacokinetics in term newborn: ¿Is it necessary to systematically monitor plasmatic levels?

Background: Gentamicin is indicated as empiric treatment for neonatal sepsis. Plasmatic levels dosification of gentamicin is a common practice. The relationship between peak plasma concentration (Cmáx) with minimum inhibitory concentration (MIC) (Cmáx/MIC) is the parameter that best predicts treatment efficacy. Aim: To determine pharmacokinetics of gentamicin in term newborn infants. Methods: Term newborn infants receiving gentamicin, without critical illness in which plasmatic levels of gentamicin was performed were included. Elimination clearance (Cl) elimination half-life (t½) and volume of distribution (Vd) were calculated. In each case the value of Cmax/MIC parameter was calculated, considering a MIC value of 1 μg/mL for Escherichia coli. Results: Thirteen newborns were included. The mean PK values were Cl: 0.26 mL/hour, Vd: 0.54 L/kg and t½: 6.8 h. Cmax/MIC was > 8 in 6 newborns. Conclusions: Pharmacokinetic parameters of gentamicin are predictable in term newborn infants. With gentamicin doses normally used Cmax/MIC values reached 8 in 6 newborns. It is necessary to review the usefulness of plasma drug monitoring and gentamicin dosage in this group of newborns.

Introducción: Gentamicina es utilizada como tratamiento empírico en la sepsis neonatal. El monitoreo de su concentración plasmática es una práctica frecuente. La relación entre la concentración plasmática máxima (Cmax) y la concentración inhibitoria mínima (Cmax/ CIM) es el parámetro que mejor predice la eficacia. Objetivo: Determinar los parámetros farmacocinéticos (FC) de gentamicina en recién nacidos (RN) de termino. Material y Métodos: Se incluyeron RN de término, sin enfermedad crítica, en tratamiento con gentamicina (4 mg/kg/24 h) en los que se realizó monitoreo de su concentración plasmática. Se determinaron: clearence de eliminación (Cl), vida media de eliminación (t½) y volumen de distribución (Vd). Se estimó la Cmax/CIM, considerando una CIM de 1 μg/mL para Escherichia coli. Resultados: Participaron 13 RN. La media de Cmax fue 8,19 μg/mL y de Cmin 0,73 μg/mL. La media de los parámetros farmacocinéticos fue: Cl 0,26 mL/h, Vd 0,54 L/kg, t½ 6,8 h. La razón Cmáx/CIM fue ≥ 8 en 6 de los 13 RN. Conclusiones: Los parámetros FC de gentamicina en RN de término, sin enfermedad crítica, son predecibles. La posología habitual no permitió obtener valores de Cmax/CIM > 8 en todos los casos. Es necesario revisar la necesidad de monitorizar su concentración plasmática en forma sistemática y la posología de gentamicina en este grupo de pacientes.

Comparación del esquema antibiótico entre la Piperacilina-Tazobactam y Amikacina vs Metronidazol y Gentamicina en el tratamiento de la apendicitis complicada en niños / Comparison between two antibiotic schemes gentamycin-metronidazole vs. piperacillin-tazobactam and amikacin in treating complicated appendectomies in children

Introducción. Los pacientes que tuvieron complicaciones infecciosas post cirugía de apendicitis siguen usualmente un esquema de tratamiento establecido de antibióticos en el Hospital San Juan de Dios (HSJD). Se realizó un análisis retrospectivo de 60 pacientes pediátricos con apendicitis complicada a quienes se les efectuó una apendicectomía abierta y se utilizó el esquema antibiótico de metronidazol y gentamicina. Objetivo. Evaluar la eficacia del esquema de antibióticos usados. Metodología. El estudio se efectuó en la Unidad de Cirugía Pediátrica del HGSJD en el período de tiempo de enero a diciembre de 2013. Se evaluaron las complicaciones infecciosas en los pacientes que requirieron la omisión de los antibióticos mencionados y el inicio de la combinación de piperacilina tazobactam ­ amikacina. Resultados. Hubo 56 (93%) pacientes en quienes el esquema inicial de metronidazol ­ gentamicina fue el único empleado sin que presentaran complicación infecciosa alguna, mientras que 4 (7%) pacientes presentaron colecciones abdominales que requirieron el cambio a piperacilina tazobactam-amikacina con lo que resolvieron la sepsis abdominal. Conclusiones. La utilización de la combinación antibiótica de metronidazol-gentamicina continúa siendo eficiente en la población pediátrica con apendicitis aguda complicada que consulta a nuestro hospital dejando el empleo de la piperacilina tazobactam y amikacina como una alternativa terapéutica útil. Palabras clave: Apendicetomía, metronidazol-gentamicina, piperacilina-tazobactam, amikacina

Introduction: A retrospective study was conducted with 60 pediatric patients with diagnosis of complicated appendicitis, in which open appendectomy was performed and treated with metronidazole and gentamycin. Objective: To evaluate efficacy between the combination of a routinely stablished treatment of metronidazole and gentamycin and piperacillin-tazobactam with amikacin in the treatment of complicated appendectomies. Methodology: This retrospective study was conducted in the Pediatric Surgery Unit of the General Hospital San Juan de Dios from January to December 2013. The postoperative complications were assessed of patients who needed a change in antibiotic therapy to piperacillin tazobactam-amikacin. Results: Fifty-six patients (93%) in which the initial antibiotic combination was used recovered without any complications. Four (7%) patients developed intraabdominal collections and needed therapy with piperacillin tazobactam­amikacin with which they resolved the abdominal sepsis. The antibiotic combination gentamycin and metronidazole is still effective in the pediatric population with complicated acute appendicitis in our hospital, leaving the use of piperacillin tazobactam ­ amikacin as a useful alternative. Keywords: Appendectomy, metronidazole-gentamycin, piperacillin tazobactam-amikacyn

Clinical pharmacology of gentamicin in neonates: regimen, toxicology and pharmacokinetics / Farmacologia clínica da gentamicina em neonatos: modalidades de uso, toxicologia e farmacocinética

Gentamicin is an aminoglycoside antibiotic. It kills bacteria by inhibiting protein synthesis and to some extent by lysing the cell envelope. Gentamicin is frequently the first choice drug because of its reliability, but also because of the long experience with its use. In combination with β-lactam antibiotics it is recommended for the treatment of sepsis or pneumonia and is active against P. aeruginosa, Enterobacter, Klebsiella and Serratia. However, gentamicin is ototoxic and nephrotoxic. The human mitochondrial genetic variant m.1555A > G has been reported to be an important cause of non-syndromic hereditary hearing dysfunction and may cause permanent hearing loss. Even short courses of gentamicin therapy in healty newborn infants can lead to abnormalities of auditory function. It is active against very resistant bacteria at peak concentrations (> 10 mg/l) that are high enough to be potentially toxic. For safe therapeutic efficacy, peak plasma concentrations of gentamicin should range from 4 to 10 mg/l; but trough concentrations, immediately before a new drug administration, must be lower that 2 mg/L to avoid toxic effects. Pharmacokinetic parameters vary considerably in infants. Half-life ranges from 5.4 to 10.0 hours, clearance 0.50 to 1.71 ml/h/kg and distribution volume from 0.4 to 0.7 l/kg. Preterm infants have a longer half-life than full-term infants. Thus, it is mandatory to monitor gentamicin serum concentrations whenever infants are treated for 48 hours or more.

A gentamicina é antibiótico do grupo dos aminoglicosídeos. Destrói bactérias por inibição de síntese proteica e, em certa medida, por lise do envelope celular. A gentamicina é a droga de primeira escolha por causa de sua atividade confiável e em virtude de longa experiência com seu uso. Em combinação com antibióticos β-lactâmicos é recomendada para o tratamento de septicemia ou pneumonia e é ativa contra P. aeruginosa, Enterobacter, Klebsiella e Serratia. No entanto, a gentamicina é ototóxica e nefrotóxica. A variante genética mitocondrial humana m.1555A > G é tida como importante causa de disfunção auditiva hereditária não-sindrômica e pode causar perda permanente da audição. Até mesmo procedimentos terapêuticos de gentamicina de curta duração em recém-nascidos sadios podem levar a anormalidades da função auditiva. É ativa contra algumas espécies de bactérias apenas em concentrações de pico (> 10 mg/l) que são suficientemente altas para produzirem efeitos tóxicos. A gentamicina deve cair a concentrações mínimas menores que 2 mg/l para evitar efeitos tóxicos. Para produzir efeitos terapêuticos, as concentrações plasmáticas máximas de gentamicina deve variar de 4 a 10 mg/l. Os parâmetros farmacocinéticos variam consideravelmente em lactentes. A meia-vida varia entre 5,4-10,0 horas, o "clearance" varia entre 0,50 e 1,71 ml/h/kg e volume de distribuição de 0,4-0,7 l/kg. Em prematuros a meia-vida é mais longa do que a de crianças nascidas a termo. Por esses motivos, sempre que lactentes são tratadas durante 48 horas ou mais, monitorizar as concentrações séricas de gentamicina é essencial.